Prelude Therapeutics (PRLD) Other financing activities (2020 - 2026)

Prelude Therapeutics has reported Other financing activities for 7 years, with the latest figure at $31000.0 in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $31000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $181000.0 (down 51.99% YoY) and the FY2025 annual result came in at $150000.0, down 60.42% from the prior year.
• Other financing activities fell to $31000.0 in Q1 2026 per PRLD's latest filing, from $58000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $320000.0 in Q2 2023 and troughed at -$317000.0 in Q3 2023.
• A 5-year average of $68866.7 and a median of $59000.0 in 2022 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2023 and 2024: Other financing activities plunged 460.23% in 2023, then surged 1893.75% in 2024.
• Over 5 years, Other financing activities stood at $126000.0 in 2022, then tumbled by 87.3% to $16000.0 in 2023, then soared by 1893.75% to $319000.0 in 2024, then slumped by 81.82% to $58000.0 in 2025, then plunged by 46.55% to $31000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $31000.0, $58000.0, and $92000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.